JPRN-C000000151已完成2 期
Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancer - Phase II study of gefitinib in patients with EGFR mutation positive- advanced non-small cell lung cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Intestinal pneumonia or lung fibrosis 2) History of severe drug allergic reaction 3) Severe infection and complication (cardio insufficiency or hemorrhage etc.) 4) Severe diarrhea 5) Bowel obstruction,ileus 6) Symptomatic brain metastasis 7) History of other malignancy 8) Pregnant women or women willing child-bearing 9) No regulatory condition because of psychological disease 10) Inadequate condition diagnosed by primary physician
研究者
相似试验
未知
不适用
PhaseII stady of gefitinib and in patients with relapsed advanced non-small cell lung cancerJPRN-C000000142Department of Medical Oncology Kinki University School of Medicine30
进行中（未招募）
不适用
Afatinib translational study in patients with EGFR mutation-positive non-squamous non-small cell lung cancer acquired resistance to osimertinibEGFR mutation-positive non-squamous non-small cell lung cancerJPRN-jRCTs071180013Ryo Toyozawa30
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
已完成
不适用
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
暂停
2 期
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT00986284Tianjin Medical University Cancer Institute and Hospital102